Summit Trail Advisors’s MacroGenics MGNX Stock Holding History

Summit Trail Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,590	Closed	-$34K	–	1179
2017 Q4	$34K	Buy	+1,590	New	+$29.7K	﹤0.01%	914

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Summit Trail Advisors's MGNX Position: Q1 2018 in Review

Summit Trail Advisors sold out of MacroGenics (MGNX) in Q1 2018, closing a stake of 1,590 shares — an estimated $34K sold.

Summit Trail Advisors first reported a position in MGNX in Q4 2017 and held it in 1 quarter. The position peaked at $34K in Q4 2017. 132 funds tracked by Wall St. Rank hold MGNX as of Q1 2018.

Summit Trail Advisors reported no remaining MacroGenics position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 1,590 MacroGenics shares in Q1 2018, an estimated $34K.
Summit Trail Advisors first reported a position in MacroGenics in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's MacroGenics position peaked at $34K in Q4 2017.
132 funds tracked by Wall St. Rank held MacroGenics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.